As a result, treatment with all-trans retinoic acid has been successfully introduced for APL patients with the PML–RAR fusion protein, leading to the differentiation of blasts into granulocytes and often inducing patient remission [87,88]. The gene discussed is RARA; the disease is acute promyelocytic leukemia.